16.10.2013 10:04 Uhr in Wirtschaft & Finanzen von Sanofi-Aventis
Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
Kurzfassung: Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reductionalirocumab monotherapy reduced "bad cholesterol three t ...
[Sanofi-Aventis - 16.10.2013] Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction
alirocumab monotherapy reduced "bad cholesterol three times more than ezetimibe
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or "bad cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15.6%, p
alirocumab monotherapy reduced "bad cholesterol three times more than ezetimibe
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Phase 3 ODYSSEY MONO trial with alirocumab, an investigational monoclonal antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), met its primary efficacy endpoint. The mean low-density lipoprotein-cholesterol (LDL-C, or "bad cholesterol) reduction from baseline to week 24, the primary efficacy endpoint of the study, was significantly greater in patients randomized to alirocumab, as compared to patients randomized to ezetimibe (47.2% vs. 15.6%, p
Weitere Informationen
Weitere Meldungen dieses Unternehmens
23.07.2014 Wechsel bei Sanofi in der Gesundheitspolitik
Erfolgreiche Pressearbeit eBook
Eine Pflichtlektüre für mehr Sichtbarkeit durch Pressemitteilungen.
Pressefach abonnieren
via RSS-Feed abonnieren
via E-Mail abonnieren
Pressekontakt
Sanofi-Aventis
65926 Frankfurt am Main
Deutschland
Drucken
Weiterempfehlen
PDF
Schlagworte
Sanofi-Aventis
65926 Frankfurt am Main
Deutschland
https://www.prmaximus.de/pressefach/sanofi-aventis-pressefach.html
Die Pressemeldung "Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction" unterliegt dem Urheberrecht.
Jegliche Verwendung dieses Textes, auch auszugsweise, erfordert die vorherige schriftliche Erlaubnis des Autors.
Autor der Pressemeldung "Sanofi and Regeneron Report Positive Top-line Results with Alirocumab from First Phase 3 Study of a PCSK9 Inhibitor for LDL Cholesterol Reduction" ist Sanofi-Aventis, vertreten durch .